Q3 ended | Q3 ended | |||
Sales | 858,089 | 1,096,360 | ||
Net Income (loss) | (382,930 | ) | (68,676 | ) |
Income per common share | ||||
- basic | (0.11 | ) | (0.02 | ) |
- diluted | (0.11 | ) | (0.02 | ) |
Weighted avg. common shares | ||||
Outstanding | ||||
- basic | 3,432,478 | 3,432,478 | ||
- diluted | 3,432,478 | 3,432,478 |
Although results for the current quarter continue to reflect a soft market and persisting problems with the global economy as a whole, a number of product orders filled in the third quarter weren’t shipped until the fourth quarter, resulting in lower sales this quarter. Management’s continued cautious approach to cash management has allowed the company to weather these worldwide issues.
Management believes that the African Swine Fever may be abating, which may lead to increasing sales of Iron Dextran. Re-establishment of worldwide sales of this product remains a top priority going forward. New markets are emerging for the company’s powdered products, and Management foresees an increase in sales of these products in the coming months.
“We are hopeful that the recovery we are seeing in some aspects of the global economy may translate to increased sales of our products in the coming months,” said
The Company’s publicly traded shares continue to be quoted on the OTC Pink Sheet platform (www.otcmarkets.com/stock/POLXF/quote).
The company continues full disclosure of its financial and operational results, which can be accessed by visiting the company website at www.Polydex.com. Product information is available at www.dextran.ca.
Company website: www.Polydex.com
Note: This press release may contain forward-looking statements, within the meaning of the United States Securities Act of 1933, as amended, and the United States Securities Exchange Act of 1934, as amended, regarding
Contact:
Investor Relations:
Source:
2022 GlobeNewswire, Inc., source